Business Context and Reporting Period
This Form 8-K Current Report was filed by Nephros, Inc. on August 10, 2018. The filing primarily addresses corporate governance changes, specifically the appointment of a new director and the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to the compensation package for the newly appointed director:
- Annual Retainer: $20,000
- Meeting Fee: $1,500 per quarterly Board meeting
- Stock Options: Grant of 85,199 options
- Exercise Price: $0.6195 per share (Fair Market Value on August 10, 2018)
Material Changes
The material change reported is the appointment of Oliver Spandow to the Board of Directors on August 10, 2018. Mr. Spandow was also appointed to the Audit Committee, Compensation Committee, and Nominating and Governance Committee. The filing confirms no prior material transactions or conflicts of interest between Mr. Spandow and the Company.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of risks and contingencies. The stock options granted to Mr. Spandow vest in three equal installments on the date of grant and the first and second anniversaries thereof.
Investor Verification Checklist
- Verify the total number of outstanding shares on a fully-diluted basis to confirm the 0.0011% calculation for the 85,199 option grant.
- Review the attached Press Release (Exhibit 99.1) for additional context on Mr. Spandow's background.
- Confirm the Company's current cash position to assess the impact of the new director's cash compensation.